Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized, prospective study to investigate the safety and efficacy of Campath-1H as an induction agent in combination with tacrolimus monotherapy compared to short-course ATG [antithymocyte globulin]-induction in combination with tacrolimus, mycophenolate mofetil and short-term steroids application in de novo SPK [simultaneous pancreas-kidney transplant] transplanted diabetic patients

Next Previous
X
Search
Trial Profile

An open-label, randomized, prospective study to investigate the safety and efficacy of Campath-1H as an induction agent in combination with tacrolimus monotherapy compared to short-course ATG [antithymocyte globulin]-induction in combination with tacrolimus, mycophenolate mofetil and short-term steroids application in de novo SPK [simultaneous pancreas-kidney transplant] transplanted diabetic patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Methylprednisolone; Mycophenolate mofetil; Prednisolone; Tacrolimus
  • Indications Kidney-pancreas transplant rejection
  • Focus Therapeutic Use
  • Acronyms SIMPATICO

    • Most Recent Events

    • 19 Jul 2012 Results presented at the 24th International Congress of the Transplantation Society.
    • 18 Jun 2012 Actual patient number is 30 according to ClinicalTrials.gov.
    • 18 Jun 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top